EGFR targeting PhosTACs as a dual inhibitory approach reveals differential downstream signaling
Zhenyi Hu(Yale Cancer Center), Craig M. Crews(Yale University)
Cited by 36
Related Papers
PROTAC targeted protein degraders: the past is prologue
|Nature Reviews Drug Discovery|2022|2.9k
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
|Nature Communications|2019|516
Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
|Communications Biology|2018|343
Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs
|ACS Central Science|2019|287
Targeted Protein Degradation by Small Molecules
|The Annual Review of Pharmacology and Toxicology|2016|203